Green Tea Catechins in Cancer Prevention and Therapy: Molecular Mechanisms, Clinical Evidence, Safety, and Future Perspectives

Main Article Content


Abstract

Green tea, derived from Camellia sinensis, is a widely consumed dietary source of bioactive polyphenols. Among its major catechins, epigallocatechin-3-gallate (EGCG) has been studied most extensively in cancer research. This review critically synthesizes phytochemical, molecular, preclinical, epidemiological, clinical, pharmacokinetic, and safety evidence to assess the potential role of green tea catechins in cancer prevention and treatment. Preclinical studies of breast, prostate, colorectal, lung, liver, oral, and hematological cancers indicate that EGCG modulates oxidative stress, inflammatory signaling, proliferation, apoptosis, cell-cycle progression, angiogenesis, epithelial–mesenchymal transition, invasion, metastasis, and epigenetic regulation. Reported molecular targets include the PI3K–AKT–mTOR, MAPK, JAK–STAT, and NF-κB signaling pathways, as well as EGFR and VEGF signaling, BCL-2 family proteins, caspases, matrix metalloproteinases, and enzymes involved in DNA methylation. A systematic review and meta-analysis reported an association between green tea or EGCG exposure and lower overall cancer risk, with variation by cancer type and study design. Clinical evidence for efficacy in established malignancies remains limited, and conventional oncological treatment remains the standard of care. By integrating mechanistic findings with human data, this review identifies gaps in clinical efficacy, pharmacokinetics, and safety that must be addressed before green tea catechins can be incorporated into evidence-based oncology.

Keywords:
Download Full-Text PDF Direct PDF file • 12318.pdf

Share Article:

Citation Metrics:

Scopus

Downloads

Download data is not yet available.

Citation Metrics & Similar Scopus Articles

Citation data unavailable from the configured source
Check Secondary Documents in Scopus
Open this article in Scopus, then check the Secondary documents tab. Use Manual Citation Fallback only for counts you have verified manually.
Open in Scopus
Similar Scopus Articles
Scopus
  1. Zhang T. (2027)
    A Manganese-Chlorella Hydrogel for an Integrated “Remove–Remodel–Repair” Strategy in Pancreatic Cancer Therapy
    Nano Micro Letters, 19(1)
  2. Bayati N. (2027)
    Preparation and Characterization of ZnMn2O4 Nanoparticles to Investigate Its Ability to Produce Reactive Oxygen Species for Application in the Treatment of Cancer by Photodynamic Therapy
    Journal of Nanostructures, 17(1), 203-216
  3. Zhang Z. (2027)
    A green molecular gel nanocomposite: Structure, rheological properties and tribological performance
    Advanced Nanocomposites, 4, 39-50

Article Details

How to Cite
Khalaf, I. M., Ali, B. M., Mohsen, R. T., & Kadhim, O. A. (2026). Green Tea Catechins in Cancer Prevention and Therapy: Molecular Mechanisms, Clinical Evidence, Safety, and Future Perspectives. Asian Journal of Science, Technology, Engineering, and Art, 4(6), 967-983. https://doi.org/10.58578/ajstea.v4i6.12318

References

Musial, C., Kuban-Jankowska, A., & Gorska-Ponikowska, M. (2020). Beneficial properties of green tea catechins. International Journal of Molecular Sciences, 21(5), Article 1744. https://doi.org/10.3390/ijms21051744

Khan, N., & Mukhtar, H. (2019). Tea polyphenols in promotion of human health. Nutrients, 11(1), Article 39. https://doi.org/10.3390/nu11010039

Yang, C. S., Wang, X., Lu, G., & Picinich, S. C. (2009). Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. Nature Reviews Cancer, 9(6), 429–439. https://doi.org/10.1038/nrc2641

Zhang, Y., Xu, Q., Hu, J., Zhang, F., Yu, Y., & Ma, L. (2025). Green tea and epigallocatechin gallate (EGCG) for cancer prevention: A systematic review and meta-analysis. American Journal of Chinese Medicine, 53(6), 1755–1784.

Mereles, D., & Hunstein, W. (2011). Epigallocatechin-3-gallate (EGCG) for clinical trials: More pitfalls than promises? International Journal of Molecular Sciences, 12(9), 5592–5603. https://doi.org/10.3390/ijms12095592

Lambert, J. D., & Elias, R. J. (2010). The antioxidant and pro-oxidant activities of green tea polyphenols: A role in cancer prevention. Archives of Biochemistry and Biophysics, 501(1), 65–72.

Singh, B. N., Shankar, S., & Srivastava, R. K. (2011). Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochemical Pharmacology, 82(12), 1807–1821.

Min, K. J., & Kwon, T. K. (2014). Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate. Integrative Medicine Research, 3(1), 16–24.

Gan, R. Y., Li, H. B., Sui, Z. Q., & Corke, H. (2018). Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review. Critical Reviews in Food Science and Nutrition, 58(6), 924–941.

Yang, C. S., & Wang, H. (2016). Cancer preventive activities of tea catechins. Molecules, 21(12), Article 1679. https://www.mdpi.com/1420-3049/21/12/1679

Fujiki, H., Watanabe, T., Sueoka, E., Rawangkan, A., & Suganuma, M. (2018). Cancer prevention with green tea and its principal constituent, EGCG: From early investigations to current focus on human cancer stem cells. Molecules and Cells, 41(2), 73–82.

Chen, D., Milacic, V., Chen, M. S., et al. (2008). Tea polyphenols, their biological effects and potential molecular targets. Histology and Histopathology, 23(4), 487–496.

Kumar, N. B., Pow-Sang, J., Egan, K. M., et al. (2015). Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention. Cancer Prevention Research, 8(10), 879–887.

Sun, C. L., Yuan, J. M., Koh, W. P., & Yu, M. C. (2006). Green tea, black tea and colorectal cancer risk: A meta-analysis of epidemiologic studies. Carcinogenesis, 27(7), 1301–1309. https://academic.oup.com/carcin/article-abstract/27/7/1301/2391057

Wang, Z. H., Gao, Q. Y., & Fang, J. Y. (2012). Green tea and incidence of colorectal cancer: Evidence from prospective cohort studies. Nutrition and Cancer, 64(8), 1143–1152.

Ni, C. X., Gong, H., Liu, Y., Qi, Y., Jiang, C. L., & Zhang, J. P. (2017). Green tea consumption and the risk of liver cancer: A meta-analysis. Nutrition and Cancer, 69(2), 211–220.

Li, M., Duan, Y., Wang, Y., Chen, L., Abdelrahim, M. E. A., & Yan, J. (2024). The effect of green tea consumption on body mass index, lipoprotein, liver enzymes, and liver cancer: An updated systemic review incorporating a meta-analysis. Critical Reviews in Food Science and Nutrition, 64(4), 1043–1051.

Shanafelt, T. D., Call, T. G., Zent, C. S., LaPlant, B., Bowen, D. A., Roos, M., Secreto, C. R., Ghosh, A. K., Kabat, B. F., Lee, M. J., Yang, C. S., Jelinek, D. F., Erlichman, C., & Kay, N. E. (2009). Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. Journal of Clinical Oncology, 27(23), 3808–3814.

Shanafelt, T. D., Call, T. G., Zent, C. S., Leis, J. F., LaPlant, B., Bowen, D. A., Roos, M., Laumann, K., Ghosh, A. K., Lesnick, C., Lee, M. J., Yang, C. S., Jelinek, D. F., Erlichman, C., & Kay, N. E. (2013). Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer, 119(2), 363–370.

Golden, E. B., Lam, P. Y., Kardosh, A., Gaffney, K. J., Cadenas, E., Louie, S. G., Petasis, N. A., Chen, T. C., & Schönthal, A. H. (2009). Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood, 113(23), 5927–5937.

Lee, M. J., Maliakal, P., Chen, L., Meng, X., Bondoc, F. Y., Prabhu, S., Lambert, G., Mohr, S., & Yang, C. S. (2002). Pharmacokinetics of tea catechins after ingestion of green tea and (−)-epigallocatechin-3-gallate by humans: Formation of different metabolites and individual variability. Cancer Epidemiology, Biomarkers & Prevention, 11(10 Pt 1), 1025–1032.

Chow, H. H. S., Cai, Y., Hakim, I. A., Crowell, J. A., Shahi, F., Brooks, C. A., Dorr, R. T., Hara, Y., & Alberts, D. S. (2003). Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and Polyphenon E in healthy individuals. Clinical Cancer Research, 9(9), 3312–3319.

Chow, H. H. S., Hakim, I. A., Vining, D. R., Crowell, J. A., Ranger-Moore, J., Chew, W. M., Celaya, C. A., Rodney, S. R., Hara, Y., & Alberts, D. S. (2005). Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clinical Cancer Research, 11(12), 4627–4633.

Clifford, M. N., van der Hooft, J. J. J., & Crozier, A. (2013). Human studies on the absorption, distribution, metabolism, and excretion of tea polyphenols. American Journal of Clinical Nutrition, 98(6 Suppl), 1619S–1630S.

Granja, A., Pinheiro, M., & Reis, S. (2016). Epigallocatechin gallate nanodelivery systems for cancer therapy. Nutrients, 8(5), Article 307. https://www.mdpi.com/2072-6643/8/5/307

EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Frutos, M. J., Galtier, P., Gott, D., Gundert-Remy, U., Lambré, C., Leblanc, J.-C., Lillegaard, I. T., Moldeus, P., Mortensen, A., Oskarsson, A., Stankovic, I., Waalkens-Berendsen, I., ... Wright, M. (2018). Scientific opinion on the safety of green tea catechins. EFSA Journal, 16(4), Article e05239. https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2018.5239

Dostal, A. M., Samavat, H., Bedell, S., et al. (2015). The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: Results of the Minnesota Green Tea Trial. Food and Chemical Toxicology, 83, 26–35.

Altinoz, H. B., & Sanlier, N. (2026). Green tea catechins and prostate cancer: Mechanisms, clinical evidence, and safety: A narrative review. BMC Cancer, 26, Article 191. https://link.springer.com/article/10.1186/s12885-025-15516-8

Samavat, H., Ursin, G., Emory, T. H., et al. (2017). A randomized controlled trial of green tea extract on mammographic density in postmenopausal women at increased risk of breast cancer. Cancer Prevention Research, 10(12), 710–718.

Shammas, M. A., Neri, P., Koley, H., Batchu, R. B., Bertheau, R. C., Munshi, V., Prabhala, R., Fulciniti, M., Tai, Y. T., Treon, S. P., Goyal, R. K., Anderson, K. C., & Munshi, N. C. (2006). Specific killing of multiple myeloma cells by (−)-epigallocatechin-3-gallate extracted from green tea: Biologic activity and therapeutic implications. Blood, 108(8), 2804–2810.